<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrea Tringali, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Guido Costamagna, MD, FACG</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced endoscopic procedure in which a specialized side-viewing upper endoscope is guided into the duodenum, allowing for instruments to be passed through the ampulla of Vater and into the biliary and pancreatic ducts. The role of ERCP in managing pancreaticobiliary disorders is mostly a therapeutic one because other accurate methods of diagnostic testing (eg, magnetic resonance cholangiopancreatography, endoscopic ultrasound [EUS]) are available without the risks associated with ERCP. </p><p>Bleeding is a serious adverse event related to ERCP, and it is most often observed after biliary or pancreatic sphincterotomy. Less common causes of bleeding include splenic, hepatic or vascular injury, endoscopic stenting or tissue sampling, and submucosal bleeding of the papilla in patients at higher risk for bleeding (eg, those with a hemostatic disorder). Because of advances in equipment, preventive techniques, and endoscopic training, ERCP-related bleeding has become relatively less common over time.</p><p>This topic will discuss preventive strategies and treatment of bleeding related to ERCP.</p><p>Other aspects of ERCP, including indications, patient preparation, and other adverse events are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/632.html" rel="external">"Overview of endoscopic retrograde cholangiopancreatography (ERCP) in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/629.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/641.html" rel="external">"Infectious adverse events related to endoscopic retrograde cholangiopancreatography (ERCP)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/634.html" rel="external">"Post-ERCP perforation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/638.html" rel="external">"Adverse events related to endoscopic retrograde cholangiopancreatography (ERCP) in adults"</a>.)</p><p></p><p>Indications for and technical aspects of biliary sphincterotomy are discussed separately. (See  <a class="medical medical_review" href="/d/html/640.html" rel="external">"Endoscopic biliary sphincterotomy"</a>.)</p><p class="headingAnchor" id="H594210069"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The reported rate of gastrointestinal bleeding related to ERCP has ranged from &lt;1 to 3 percent [<a href="#rid1">1-7</a>]. In a review of 21 studies including over 16,000 patients undergoing ERCP, 226 patients developed bleeding (1.3 percent), with severe bleeding in 66 patients [<a href="#rid4">4</a>]. The mortality rate related to post-ERCP bleeding was 0.05 percent. </p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS AND GRADING SEVERITY</span><span class="headingEndMark"> — </span>The definition of clinically significant post-ERCP bleeding has varied across studies, and we agree with consensus from professional societies that defines a bleeding event as hematemesis, melena, and/or drop in hemoglobin by &gt;2 g [<a href="#rid8">8,9</a>]. In addition, bleeding severity is graded as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Procedure aborted because of bleeding and/or unplanned hospital admission (&lt;4 nights). </p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Unplanned hospital admission for 4 to 10 nights; intensive care unit (ICU) admission for one night; requiring blood transfusion; requiring repeat endoscopy; and/or requiring interventional radiology.</p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Unplanned hospital admission for &gt;10 nights; ICU admission for &gt;1 night; and/or need for surgery.</p><p></p><p>This classification system for bleeding events facilitates tracking and studying ERCP-related adverse events, although it does not play a role in routine clinical practice.</p><p class="headingAnchor" id="H5"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Most risk factors for bleeding related to ERCP can be categorized as follows [<a href="#rid8">8,10-15</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Patient-related factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Disorders of hemostasis [<a href="#rid10">10-12</a>] (see  <a class="medical medical_review" href="/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Use of anticoagulants or antiplatelet agents</p><p class="bulletIndent2"><span class="glyph">•</span>Cirrhosis [<a href="#rid13">13</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>End-stage kidney disease/dialysis [<a href="#rid12">12,14</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Acute cholangitis [<a href="#rid10">10</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Anatomic factors [<a href="#rid11">11,16</a>] – Ampullary tumor or stenosis [<a href="#rid11">11,16</a>], surgically altered anatomy (eg, Billroth II gastrectomy), impacted gallstone [<a href="#rid11">11</a>] (see  <a class="medical medical_review" href="/d/html/676.html" rel="external">"Endoscopic retrograde cholangiopancreatography (ERCP) after Billroth II reconstruction"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procedure-related factors (see  <a class="medical medical_review" href="/d/html/640.html" rel="external">"Endoscopic biliary sphincterotomy", section on 'Electrosurgical devices'</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skewed direction of sphincterotomy incision [<a href="#rid17">17</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Sudden, uncontrolled papillary incision when using a conventional electrosurgical generator (ie, "zipper" cut) [<a href="#rid18">18</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Use of pure-cut electrical current during sphincterotomy [<a href="#rid18">18</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Extension of previous sphincterotomy [<a href="#rid10">10,19</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopic snare papillectomy [<a href="#rid20">20</a>] (see  <a class="medical medical_review" href="/d/html/649.html" rel="external">"Ampullary adenomas: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopist-related factors: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low case volume (eg, ≤1 ERCP per week) [<a href="#rid10">10</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopists with limited experience [<a href="#rid15">15</a>] </p><p></p><p>The severity of bleeding at presentation has been associated with risk for rebleeding, despite initially successful endoscopic hemostasis. In a study including 161 patients with post-ERCP bleeding related to sphincterotomy, 35 patients (22 percent) had rebleeding after initial endoscopic hemostasis was achieved. Factors associated with a higher risk of rebleeding included bilirubin level &gt;10 mg/dL and severe bleeding during the initial presentation (defined as blood transfusion of ≥5 units or the need for angiographic or surgical intervention) [<a href="#rid21">21</a>]. </p><p class="headingAnchor" id="H9"><span class="h1">PREVENTIVE STRATEGIES</span></p><p class="headingAnchor" id="H2465685341"><span class="h2">Goals</span><span class="headingEndMark"> — </span>For patients undergoing ERCP, the goal of a preventive strategy is to reduce the risk of post-ERCP bleeding and related events (eg, blood transfusion requirement, repeat endoscopic intervention). </p><p class="headingAnchor" id="H3926975368"><span class="h2">Optimizing coagulation status</span><span class="headingEndMark"> — </span>Preventive strategies involve assessing and optimizing the patient's coagulation status:</p><p class="bulletIndent1"><span class="glyph">●</span>Preprocedure testing – Most patients undergoing interventional ERCP will have had laboratory tests (eg, complete blood count and prothrombin time/international normalized ratio [INR]) as part of the diagnostic evaluation for the underlying condition, thereby mitigating the need for additional laboratory testing. </p><p></p><p class="bulletIndent1">For patients with no recent laboratory testing, we typically measure complete blood count and INR. For high-risk procedures such as ERCP, commonly used thresholds for performing the procedure include platelet count &gt;50,000/microL and an INR &lt;1.5 [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent1">However, some advanced endoscopists restrict laboratory testing to selected patients, and this is consistent with society guidelines [<a href="#rid22">22,23</a>]. These patient groups include those with any of the following conditions: active bleeding; a known or suspected disorder of hemostasis (eg, immune thrombocytopenia); use of anticoagulants or prolonged antibiotics; chronic cholestasis; cirrhosis; or malnutrition. (See  <a class="medical medical_review" href="/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimizing coagulation status for patients with specific conditions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on antithrombotic agents – Adjusting antithrombotic medications is discussed below. (See <a class="local">'Adjusting antithrombotic medications'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with disorders of hemostasis – We consult with the clinician(s) managing the patient's underlying disorder of hemostasis (eg, hemophilia, von Willebrand disease) to estimate the patient's bleeding risk and to guide periprocedural management. These issues are addressed separately. (See  <a class="medical medical_review" href="/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a> and  <a class="medical medical_review" href="/d/html/1947.html" rel="external">"Uremic platelet dysfunction", section on 'Prevention of bleeding'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with cirrhosis – Patients with cirrhosis have hemostatic abnormalities that may increase the risk of bleeding in addition to increased portal pressure that leads to gastroesophageal varices [<a href="#rid24">24</a>]. Periprocedural management is discussed separately. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease", section on 'Invasive procedures'</a>.)</p><p></p><p class="headingAnchor" id="H1656492698"><span class="h2">Adjusting antithrombotic medications</span></p><p class="headingAnchor" id="H2205366514"><span class="h3">Factors that guide decision-making</span><span class="headingEndMark"> — </span>For patients undergoing ERCP, the management of antithrombotic agents is individualized and informed by the patient's risk of thromboembolic complications in the absence of therapy, specific features of the antithrombotic agent, and the procedure-related bleeding risk  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 1</a>). ERCP-guided interventions that are high risk for bleeding include biliary or pancreatic sphincterotomy, papillectomy, and stricture dilation, whereas stent placement is associated with a lower bleeding risk [<a href="#rid22">22</a>]. </p><p>We typically consult with the clinician who is managing the patient's medication (eg, cardiologist, neurologist) to estimate the patient's thrombotic risk and to determine if antithrombotic therapy can be safely interrupted. (See  <a class="medical medical_review" href="/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a>.)</p><p>Antithrombotic agents have been associated with increased risk of bleeding related to ERCP with sphincterotomy [<a href="#rid25">25-30</a>]<em>.</em> In a large cohort study of patients who underwent ERCP with sphincterotomy, the baseline risk for bleeding of any severity in the absence of antithrombotic therapy was 2.3 percent [<a href="#rid25">25</a>]. The study evaluated associations between bleeding risk and antiplatelet or anticoagulation therapy, using propensity score analysis to control for confounding variables such as age, sex, cirrhosis, kidney disease, and thrombocytopenia. Antiplatelet therapy (excluding <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) was associated with twofold higher risk of bleeding compared with no antithrombotic therapy (adjusted odds ratio [aOR] 2.2, 95% CI 1.43-3.56; this amounts to an absolute risk of approximately 5 percent, assuming a baseline risk of 2.3 percent) [<a href="#rid25">25</a>]. Anticoagulant use (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, direct oral anticoagulants [DOACs]) was associated with a three- to four-fold higher risk of bleeding (aOR 3.6, 95% CI 2.58-5.06; this amounts to an absolute risk of approximately 8 percent). Patients who resumed anticoagulants within 24 hours of sphincterotomy had higher bleeding risk compared with no anticoagulant use within 24 hours (14 versus 5 percent; aOR 2.69, 95% CI 1.75-4.14). However, the risk of blood transfusion was not significantly different for patients who developed bleeding compared with the control group. In an earlier case-control study of over 61,000 patients who underwent ERCP with either sphincterotomy or papillary balloon dilation for choledocholithiasis, rates of severe bleeding were higher in patients receiving anticoagulants (mainly warfarin) compared with non-users for both sphincterotomy (1.6 versus 0.8 percent) and balloon dilation (3 versus 0.7 percent) [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H14"><span class="h3">Antiplatelet agents (excluding aspirin)</span><span class="headingEndMark"> — </span>Most patients on antiplatelet therapy (excluding <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) generally discontinue the antiplatelet agent (eg, a P2Y<sub>12 </sub>receptor blocker such as <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a>) prior to interventional ERCP [<a href="#rid22">22,31</a>]. The time interval for interrupting therapy and for restarting therapy after the procedure depends on the specific antiplatelet agent. These issues and the approach to adjusting dual antiplatelet therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a>.)</p><p class="headingAnchor" id="H2335642463"><span class="h3">Aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> therapy, especially if given for secondary prevention, is not interrupted prior to most endoscopic procedures. </p><p>For patients who are undergoing ERCP and selected high-risk interventions (eg, snare papillectomy), the approach depends on the endoscopist's preference [<a href="#rid32">32</a>]. Some endoscopists do not interrupt <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> regardless of the indication, especially if aspirin is used for secondary prophylaxis [<a href="#rid31">31</a>]. However, some endoscopists discontinue aspirin for five to seven days prior to ERCP for patients who are using aspirin for primary prevention (ie, patients with no history of cardiovascular or cerebrovascular disease).</p><p class="headingAnchor" id="H15"><span class="h3">Anticoagulants</span><span class="headingEndMark"> — </span>Patients on chronic anticoagulation (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, direct oral anticoagulants [DOACs]), generally require interruption of therapy prior to interventional ERCP. Patients at high risk of thromboembolism may be managed with bridging therapy with a heparin product. For patients who discontinue warfarin prior to ERCP, the goal INR is &lt;1.5 [<a href="#rid22">22</a>]. </p><p>For high-risk endoscopic procedures in patients receiving <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, or <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, guidelines from multiple societies recommend that the last dose is taken &gt;48 hours before a high-risk endoscopic procedure and that patients on <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> receive the last dose &gt;72 hours before the procedure. </p><p>The timing for restarting anticoagulation is individualized and informed by the patient's thrombotic risk, specific anticoagulant, and endoscopic intervention. As an example, for patients at low to moderate risk of thromboembolism who had biliary sphincterotomy, we usually restart <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in three days, whereas we restart DOACs in five days. Management of anticoagulants for patients undergoing ERCP is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Endoscopic methods</span><span class="headingEndMark"> — </span>Clinical experience and observational studies support the following endoscopic techniques for minimizing the risk of bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span>Sphincterotomy technique – Bleeding may be prevented or limited by positioning the wire to contact the papilla between 11 to 1 o'clock and performing a slow, gradual incision of the papillary infundibulum [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/640.html" rel="external">"Endoscopic biliary sphincterotomy", section on 'Technique'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrosurgical devices – Electrical current is applied to the cutting wire of the sphincterotome via an electrosurgical device. Most endoscopists use blended (or mixed) current consisting of both cut and coagulation for sphincterotomy because it has been associated with lower risk of bleeding [<a href="#rid18">18</a>]. The principles of electrocautery and use of electrosurgical devices during ERCP are discussed separately. (See  <a class="medical medical_review" href="/d/html/640.html" rel="external">"Endoscopic biliary sphincterotomy", section on 'Electrosurgical devices'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternatives to sphincterotomy for high-risk patients – For treatment of small bile duct stones in patients with hemostatic disorders, endoscopic papillary balloon dilation (EPBD) may reduce the risk of bleeding compared with standard sphincterotomy alone [<a href="#rid34">34,35</a>]. However, EPBD has been associated with an increased risk of post-ERCP pancreatitis. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/674.html" rel="external">"Endoscopic management of bile duct stones"</a> and  <a class="medical medical_review" href="/d/html/631.html" rel="external">"Endoscopic balloon dilation for removal of bile duct stones"</a>.) </p><p></p><p class="headingAnchor" id="H591988765"><span class="h2">Post-procedure care</span><span class="headingEndMark"> — </span>Post-procedure strategies to minimize the risk of bleeding focus on the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Timing for resuming non-steroidal anti-inflammatory drugs (NSAIDs; including <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>) – We advise patients who undergo interventional ERCP to avoid NSAIDs and aspirin (if it is being given for primary prevention) for five days following the procedure. If aspirin is being taken for secondary prevention, we instruct patients to resume aspirin after ERCP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extended observation for higher risk patients – For patients with cirrhosis and/or portal hypertension, we typically extend the post-procedure observation time to approximately 24 hours (ie, overnight hospital admission) because such patients are at increased risk for bleeding [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">PATIENTS WITH ERCP-RELATED BLEEDING</span></p><p class="headingAnchor" id="H1271971420"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Bleeding after interventional ERCP is often related to sphincterotomy but is rarely life-threatening. The timing of presentation can range from immediate bleeding during the procedure to several weeks later; however, most patients present at least 24 hours after the procedure [<a href="#rid36">36-38</a>]. A patient with bleeding typically reports melena that may vary in frequency (eg, ranging from a single episode to multiple episodes over several hours or days). Most patients remain hemodynamically stable. However, some patients report hematemesis and/or exhibit signs of hypovolemia, such as tachycardia or hypotension.  </p><p class="headingAnchor" id="H2459362951"><span class="h2">Initial resuscitation and management</span><span class="headingEndMark"> — </span>Most patients with ERCP-related bleeding respond to supportive measures and endoscopic therapy without the need for further intervention (eg, surgery). </p><p>The initial evaluation and management of a patient with suspected bleeding related to ERCP are similar to the approach for patients with upper gastrointestinal (GI) bleeding from other sources  (<a class="graphic graphic_table graphicRef72195" href="/d/graphic/72195.html" rel="external">table 2</a>). Patients who report melena, hematemesis, or symptoms of hypotension (eg, dizziness) following ERCP should be evaluated promptly. </p><p>Signs of hypovolemia (tachycardia or hypotension) are suggestive of hemodynamic instability, and initial laboratory testing includes a complete blood count, serum chemistries, and coagulation studies. Gastroenterology consultation should be obtained at the time of the patient's presentation. The evaluation and management of patients with upper GI bleeding, including clinical assessment, fluid resuscitation, and blood transfusion, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a>.)</p><p>For patients with severe bleeding resulting in hemodynamic instability (ie, tachycardia and/or hypotension that does not respond to resuscitation with fluid or blood), we obtain interventional radiology and surgery consults to provide a multidisciplinary approach to further intervention. (See <a class="local">'Refractory bleeding'</a> below.)</p><p class="headingAnchor" id="H3889272974"><span class="h2">Endoscopic evaluation</span><span class="headingEndMark"> — </span>For patients with suspected post-ERCP bleeding, we perform endoscopy with a side-viewing endoscope within 24 hours of hospital admission. If side-viewing endoscopy does not identify the source of bleeding (eg, sphincterotomy site), we perform forward-viewing upper endoscopy to exclude other sources (eg, peptic ulcer disease). When a bleeding site is identified, we use endoscopic methods to achieve hemostasis and prevent recurrent bleeding. (See <a class="local">'Endoscopic methods for hemostasis'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h2">Endoscopic methods for hemostasis</span><span class="headingEndMark"> — </span>Most patients with ERCP-related bleeding can be managed endoscopically and rarely require further intervention such as angiographic methods (eg, embolization) or surgery. Initial endoscopic treatment usually consists of injection of diluted <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> alone or in combination with thermal coagulation or endoscopic clip placement. If hemostasis is not achieved or if bleeding recurs following initial therapy, subsequent options include placing a temporary, fully covered metal stent in the bile duct, or using hemostatic agents (eg, hemostatic powder). </p><p>With all endoscopic methods, we avoid manipulating the lower border of the sphincterotomy site to avoid trauma to the pancreatic duct and minimize the risk of post-ERCP pancreatitis  (<a class="graphic graphic_picture graphicRef113782" href="/d/graphic/113782.html" rel="external">picture 1</a>) [<a href="#rid39">39</a>].  </p><p>Although several endoscopic techniques are available to control bleeding, studies comparing these techniques alone or in combination are limited. (See <a class="local">'Initial interventions'</a> below and <a class="local">'Subsequent interventions'</a> below.)</p><p class="headingAnchor" id="H19"><span class="h3">Initial interventions</span><span class="headingEndMark"> — </span>Initial endoscopic intervention typically involves submucosal injection of diluted <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> with or without thermal coagulation or endoscopic clip placement:</p><p class="bulletIndent1"><span class="glyph">●</span>Submucosal injection of diluted <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> – Initial therapy for bleeding is typically endoscopic injection with diluted epinephrine through a sclerotherapy needle  (<a class="graphic graphic_picture graphicRef128179" href="/d/graphic/128179.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef128180" href="/d/graphic/128180.html" rel="external">picture 3</a>). We typically use a solution of epinephrine diluted with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (1:10,000) to inject the submucosa in aliquots of 0.5 to 1 mL at the apex, right side, and left side of the duodenal mucosa surrounding the sphincterotomy. The site usually requires a total volume of epinephrine solution ranging from 1 to 3 mL to achieve hemostasis. We do not inject the lower border of the sphincterotomy (ie, 6 o'clock position) because it is in close proximity to the pancreatic duct orifice.   </p><p></p><p class="bulletIndent1">We use injection therapy because it results in local tamponade and hemostasis. However, published studies on injection therapy in this setting are limited [<a href="#rid12">12,40,41</a>]. In an observational study including 19 patients with post-sphincterotomy bleeding, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> injection was associated with initial hemostasis in 18 patients (95 percent) and no rebleeding [<a href="#rid41">41</a>]. In a study including 59 patients with post-sphincterotomy bleeding, rates of achieving hemostasis were not significantly different for epinephrine injection alone compared with epinephrine injection plus thermal coagulation (96 versus 100 percent) [<a href="#rid40">40</a>]. However, it was unclear whether combination therapy was used selectively for ongoing bleeding after monotherapy with epinephrine injection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thermal methods – We use a thermal method for patients with a visible vessel or an area of active bleeding because it is effective for achieving long term hemostasis [<a href="#rid40">40,42,43</a>]. Modalities to perform thermal coagulation include a contact probe such as bipolar electrocautery probe (BICAP), monopolar coagulating forceps, or the wire of the sphincterotome. In most cases, the choice among modalities is informed by equipment availability, position/orientation of the bleeding site, and clinician preference. As an example, BICAP can be used both perpendicularly and tangentially relative to the bleeding lesion. The technical aspects of using a contact thermal device are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/2589.html" rel="external">"Contact thermal devices for the treatment of bleeding peptic ulcers"</a>.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic clips – Placement of endoscopic clips onto the bleeding site may be used in combination with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> injection when there is a visible vessel or bleeding persists after injection [<a href="#rid44">44-46</a>]. However, deploying clips through a duodenoscope may be technically challenging because of the elevator mechanism at the scope's tip. To overcome these issues, flexible, shorter endoscopic clips that may be more easily delivered through a duodenoscope have become commercially available. Alternatively, clips with a standard design may be delivered through a cap-fitted, forward-viewing scope. </p><p></p><p class="bulletIndent1">When using endoscopic clips, we place them at the upper border of the sphincterotomy site to avoid the pancreatic orifice, which is in close proximity to the lower border  (<a class="graphic graphic_picture graphicRef141060" href="/d/graphic/141060.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef141061" href="/d/graphic/141061.html" rel="external">picture 5</a>). Principles of endoscopic clip application are discussed separately. (See  <a class="medical medical_review" href="/d/html/2668.html" rel="external">"Endoscopic clip therapy in the gastrointestinal tract: Bleeding lesions and beyond"</a>.) </p><p></p><p class="bulletIndent1">Limited observational data suggested that endoscopic clip placement was associated with successful hemostasis. In a study of 57 patients with persistent bleeding related to sphincterotomy despite initial treatment with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> or balloon tamponade, endoscopic clip placement via a forward-viewing endoscope was associated with hemostasis in all patients [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H3222699869"><span class="h3">Subsequent interventions</span><span class="headingEndMark"> — </span>When hemostasis is not achieved with initial intervention, subsequent endoscopic options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fully covered, self-expandable metal stent – Temporary placement of a fully covered, self-expandable metal stent (SEMS) in the common bile duct is an option for post-sphincterotomy bleeding refractory to initial endoscopic therapies and for bleeding originating from the mid/distal common bile duct. We remove the covered SEMS in four to six weeks after placement to avoid the risk of adverse events related to long-term, indwelling metal stents (eg, liver abscess). Data from case series suggested that fully covered SEMS placement was effective for controlling refractory bleeding with success rates of 100 percent in most series [<a href="#rid47">47-51</a>].</p><p></p><p class="bulletIndent1">Rarely, the use of a covered pancreatic metal stent has been reported for achieving hemostasis for severe bleeding after pancreatic sphincterotomy [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemostatic sprays – A hemostatic spray such as nanopowder is an alternative when first-line endoscopic therapies are technically challenging because of the position or size of the bleeding lesion. In a case report of a patient with severe post-sphincterotomy bleeding, application of hemostatic spray resulted in hemostasis and without complications such as biliary obstruction [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1">Technique for applying hemostatic spray and its mechanism of action are discussed separately. (See  <a class="medical medical_review" href="/d/html/2573.html" rel="external">"Overview of the treatment of bleeding peptic ulcers", section on 'Hemostatic sprays'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrin sealant – Preliminary data suggested that fibrin sealant may be an alternative for treating post-sphincterotomy bleeding that is refractory to other endoscopic interventions. In a study including 70 patients with persistent post-sphincterotomy bleeding despite endoscopic therapy, one treatment with injection of fibrin sealant was associated with hemostasis in 64 patients (91 percent) [<a href="#rid54">54</a>]. However, limitations to using fibrin sealant include risk of biliary and pancreatic duct obstruction, technical challenges with sealant preparation and injection, and cost. </p><p></p><p class="headingAnchor" id="H1380052868"><span class="h3">Other endoscopic options</span><span class="headingEndMark"> — </span>Balloon tamponade is an option for short-term hemostasis during ERCP in patients with immediate post-sphincterotomy bleeding [<a href="#rid10">10,55</a>]. We use the balloon of a stone extraction catheter and inflate it at the sphincterotomy site. We maintain balloon insufflation for one to two minutes after the bleeding stops. If bleeding recurs after removing the balloon, we use an additional method of hemostasis such as injecting the site with diluted <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> solution. (See <a class="local">'Initial interventions'</a> above.) </p><p class="headingAnchor" id="H601225572"><span class="h2">Refractory bleeding</span><span class="headingEndMark"> — </span>Options for patients with persistent or recurrent post-ERCP bleeding despite endoscopic intervention include angiographic therapy (eg, selective embolization) and surgery.</p><p>Transcatheter arterial embolization has been effective for controlling bleeding refractory to endoscopic therapy [<a href="#rid56">56-58</a>]. Embolization works by mechanically occluding the arterial supply to the bleeding site; thus, it carries the risk of bowel wall ischemia and infarction. In addition, it may be technically challenging to access the bleeding vessel, and expertise in interventional radiology is required. In a retrospective study including 34 patients with post-sphincterotomy bleeding refractory to endoscopic therapy, transcatheter embolization was associated with initial hemostasis in 33 patients (97 percent) with recurrent bleeding in three patients (9 percent) [<a href="#rid58">58</a>].</p><p>Angiographic methods to achieve hemostasis in patients with upper gastrointestinal bleeding are discussed separately. (See  <a class="medical medical_review" href="/d/html/2540.html" rel="external">"Angiographic control of nonvariceal gastrointestinal bleeding in adults"</a>.) </p><p>Surgery is rarely necessary for patients with ERCP-related bleeding because less invasive methods are effective for achieving hemostasis. Surgical options include converting the sphincterotomy to a sutured sphincteroplasty and oversewing the bleeding artery at the apex of the sphincterotomy. (See  <a class="medical medical_review" href="/d/html/15093.html" rel="external">"Surgical common bile duct exploration"</a>.)</p><p class="headingAnchor" id="H1381515128"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118263.html" rel="external">"Society guideline links: Endoscopic retrograde cholangiopancreatography (ERCP)"</a>.)</p><p class="headingAnchor" id="H82862213"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2006.html" rel="external">"Patient education: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H70566318"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Bleeding related to interventional endoscopic retrograde cholangiopancreatography (ERCP) is a serious adverse event. Reported rates of post-ERCP bleeding range from &lt;1 to 3 percent. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Most risk factors for bleeding related to ERCP can be categorized as follows (see <a class="local">'Risk factors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patient-related (eg, hemostatic disorder, use of antithrombotic agents, end-stage liver and/or kidney disease, acute cholangitis, surgically altered anatomy)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Procedure-related (eg, skewed direction of sphincterotomy, extension of previous sphincterotomy, endoscopic papillectomy)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopist-related (eg, low case volume)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive strategies</strong> – Measures to prevent post-ERCP bleeding include (see <a class="local">'Preventive strategies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessing and optimizing the patient's coagulation status. (See <a class="local">'Optimizing coagulation status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjusting antithrombotic agents – Management of antithrombotic agents (ie, anticoagulants and antiplatelet agents ) is informed by the patient's risk of thromboembolic complications in the absence of therapy, specific features of the antithrombotic agent, and the procedure-related bleeding risk  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 1</a>). ERCP-guided interventions that are high risk for bleeding include biliary or pancreatic sphincterotomy, papillectomy, and stricture dilation, whereas stent placement is associated with a lower bleeding risk. (See <a class="local">'Adjusting antithrombotic medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of sphincterotomy techniques such as precise positioning of the cutting wire and applying blended electrosurgical current. (See <a class="local">'Endoscopic methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ERCP-related bleeding</strong> – Bleeding after ERCP is often related to sphincterotomy but is rarely life-threatening.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical features</strong> – The timing of presentation can range from immediate bleeding during the procedure to several weeks later. However, most patients present at least 24 hours after the procedure. Melena is the most common presenting symptom.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial resuscitation and management</strong> – The initial evaluation and management of a patient with suspected bleeding related to ERCP are similar to the approach for patients with upper gastrointestinal bleeding from other sources  (<a class="graphic graphic_table graphicRef72195" href="/d/graphic/72195.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endoscopic evaluation and methods for hemostasis</strong> – For patients with suspected post-ERCP bleeding, we suggest upper endoscopy for evaluation and therapeutic intervention (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We perform endoscopy within 24 hours of hospital admission and typically begin by using a side-viewing endoscope. If the bleeding source is not identified with side-viewing endoscopy, we perform forward-viewing upper endoscopy. (See <a class="local">'Endoscopic evaluation'</a> above.)</p><p></p><p class="bulletIndent2">Most patients can be managed endoscopically and rarely require further intervention such as surgery or angiographic methods (eg, embolization). Initial endoscopic treatment usually consists of injection of diluted <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> alone or in combination with thermal coagulation or endoscopic clip placement. If hemostasis is not achieved or bleeding recurs following initial endoscopic therapy, subsequent options include placing a temporary, fully covered self-expandable metal stent (SEMS) or using hemostatic agents (eg, hemostatic powder). (See <a class="local">'Endoscopic methods for hemostasis'</a> above.)</p><p></p><p class="headingAnchor" id="H2705964184"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledge Francesco Ferrara, MD, and Silvano Loperfido, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Chandrasekhara V, Khashab MA, et al. Adverse events associated with ERCP. Gastrointest Endosc 2017; 85:32.</a></li><li><a class="nounderline abstract_t">Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39:793.</a></li><li><a class="nounderline abstract_t">Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol 2009; 104:31.</a></li><li><a class="nounderline abstract_t">Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102:1781.</a></li><li><a class="nounderline abstract_t">Suissa A, Yassin K, Lavy A, et al. Outcome and early complications of ERCP: a prospective single center study. Hepatogastroenterology 2005; 52:352.</a></li><li><a class="nounderline abstract_t">Watanabe H, Yoneda M, Tominaga K, et al. Comparison between endoscopic papillary balloon dilatation and endoscopic sphincterotomy for the treatment of common bile duct stones. J Gastroenterol 2007; 42:56.</a></li><li><a class="nounderline abstract_t">Nakaji S, Hirata N, Matsui H, et al. Hemodialysis is a strong risk factor for post-endoscopic sphincterotomy bleeding in patients with choledocholithiasis. Endosc Int Open 2018; 6:E568.</a></li><li><a class="nounderline abstract_t">Dumonceau JM, Kapral C, Aabakken L, et al. ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020; 52:127.</a></li><li><a class="nounderline abstract_t">Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71:446.</a></li><li><a class="nounderline abstract_t">Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.</a></li><li><a class="nounderline abstract_t">Kim HJ, Kim MH, Kim DI, et al. Endoscopic hemostasis in sphincterotomy-induced hemorrhage: its efficacy and safety. Endoscopy 1999; 31:431.</a></li><li><a class="nounderline abstract_t">Wilcox CM, Canakis J, Mönkemüller KE, et al. Patterns of bleeding after endoscopic sphincterotomy, the subsequent risk of bleeding, and the role of epinephrine injection. Am J Gastroenterol 2004; 99:244.</a></li><li><a class="nounderline abstract_t">Inamdar S, Berzin TM, Berkowitz J, et al. Decompensated cirrhosis may be a risk factor for adverse events in endoscopic retrograde cholangiopancreatography. Liver Int 2016; 36:1457.</a></li><li><a class="nounderline abstract_t">Hori Y, Naitoh I, Nakazawa T, et al. Feasibility of endoscopic retrograde cholangiopancreatography-related procedures in hemodialysis patients. J Gastroenterol Hepatol 2014; 29:648.</a></li><li><a class="nounderline abstract_t">Lee HJ, Cho CM, Heo J, et al. Impact of Hospital Volume and the Experience of Endoscopist on Adverse Events Related to Endoscopic Retrograde Cholangiopancreatography: A Prospective Observational Study. Gut Liver 2020; 14:257.</a></li><li><a class="nounderline abstract_t">Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417.</a></li><li><a class="nounderline abstract_t">Yan J, Zhou CX, Wang C, et al. Risk factors for delayed hemorrhage after endoscopic sphincterotomy. Hepatobiliary Pancreat Dis Int 2020; 19:467.</a></li><li><a class="nounderline abstract_t">Verma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastrointest Endosc 2007; 66:283.</a></li><li><a class="nounderline abstract_t">Leung JW, Chan FK, Sung JJ, Chung S. Endoscopic sphincterotomy-induced hemorrhage: a study of risk factors and the role of epinephrine injection. Gastrointest Endosc 1995; 42:550.</a></li><li><a class="nounderline abstract_t">Kang SH, Kim KH, Kim TN, et al. Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study. BMC Gastroenterol 2017; 17:69.</a></li><li><a class="nounderline abstract_t">Lee MH, Tsou YK, Lin CH, et al. Predictors of re-bleeding after endoscopic hemostasis for delayed post-endoscopic sphincterotomy bleeding. World J Gastroenterol 2016; 22:3196.</a></li><li><a class="nounderline abstract_t">Veitch AM, Radaelli F, Alikhan R, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy 2021; 53:947.</a></li><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Pasha SF, Acosta R, et al. Routine laboratory testing before endoscopic procedures. Gastrointest Endosc 2014; 80:28.</a></li><li><a class="nounderline abstract_t">Mashiana HS, Dhaliwal AS, Sayles H, et al. Endoscopic retrograde cholangiopancreatography in cirrhosis - a systematic review and meta-analysis focused on adverse events. World J Gastrointest Endosc 2018; 10:354.</a></li><li><a class="nounderline abstract_t">Chandan S, Desai A, Dahiya DS, et al. Risk of post-sphincterotomy bleeding with antiplatelet and anticoagulant use: a propensity-matched analysis of the U.S. Collaborative Network. Gastrointest Endosc 2023; 97:1129.</a></li><li><a class="nounderline abstract_t">Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25:579.</a></li><li><a class="nounderline abstract_t">Lee MG, Kim J, Lee SH, et al. Effect of sustained use of platelet aggregation inhibitors on post-endoscopic sphincterotomy bleeding. Dig Endosc 2014; 26:737.</a></li><li><a class="nounderline abstract_t">Hamada T, Yasunaga H, Nakai Y, et al. Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents. Endoscopy 2015; 47:997.</a></li><li><a class="nounderline abstract_t">Zakko A, Zakko L, Grimshaw AA, Laine L. Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy. Dig Dis Sci 2022; 67:4161.</a></li><li><a class="nounderline abstract_t">Dahale AS, Gupta M, Saxena P, et al. Endoscopic retrograde cholangiopancreaticography-related complications - Experience from tertiary care teaching centre over half a decade. J Minim Access Surg 2022; 18:526.</a></li><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3.</a></li><li><a class="nounderline abstract_t">Spadaccini M, Fugazza A, Frazzoni L, et al. Endoscopic papillectomy for neoplastic ampullary lesions: A systematic review with pooled analysis. United European Gastroenterol J 2020; 8:44.</a></li><li><a class="nounderline abstract_t">Ratani RS, Mills TN, Ainley CC, Swain CP. Electrophysical factors influencing endoscopic sphincterotomy. Gastrointest Endosc 1999; 49:43.</a></li><li><a class="nounderline abstract_t">Hung TH, Tseng CW, Chen YC, et al. Endoscopic papillary balloon dilation decreases the risk of bleeding in cirrhotic patients compared with endoscopic biliary sphincterotomy: A national population-based study. Medicine (Baltimore) 2019; 98:e16529.</a></li><li><a class="nounderline abstract_t">Mok SR, Arif M, Diehl DL, et al. Safety and efficacy of minimal biliary sphincterotomy with papillary balloon dilation (m-EBS+EPBD) in patients using clopidogrel or anticoagulation. Endosc Int Open 2017; 5:E157.</a></li><li><a class="nounderline abstract_t">Ferreira LE, Fatima J, Baron TH. Clinically significant delayed postsphincterotomy bleeding: a twelve year single center experience. Minerva Gastroenterol Dietol 2007; 53:215.</a></li><li><a class="nounderline abstract_t">Freeman ML, Nelson DB, Sherman S, et al. Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc 1999; 49:580.</a></li><li><a class="nounderline abstract_t">Ho KY, Montes H, Sossenheimer MJ, et al. Features that may predict hospital admission following outpatient therapeutic ERCP. Gastrointest Endosc 1999; 49:587.</a></li><li><a class="nounderline abstract_t">Lin WC, Lin HH, Hung CY, et al. Clinical endoscopic management and outcome of post-endoscopic sphincterotomy bleeding. PLoS One 2017; 12:e0177449.</a></li><li><a class="nounderline abstract_t">Tsou YK, Lin CH, Liu NJ, et al. Treating delayed endoscopic sphincterotomy-induced bleeding: epinephrine injection with or without thermotherapy. World J Gastroenterol 2009; 15:4823.</a></li><li><a class="nounderline abstract_t">Parlak E, Dişibeyaz S, Köksal AŞ, et al. Factors affecting the success of endoscopic treatment of sphincterotomy bleeding. Clin Res Hepatol Gastroenterol 2013; 37:391.</a></li><li><a class="nounderline abstract_t">Katsinelos P, Kountouras J, Chatzimavroudis G, et al. Endoscopic hemostasis using monopolar coagulation for postendoscopic sphincterotomy bleeding refractory to injection treatment. Surg Laparosc Endosc Percutan Tech 2010; 20:84.</a></li><li><a class="nounderline abstract_t">Ferreira LE, Baron TH. Post-sphincterotomy bleeding: who, what, when, and how. Am J Gastroenterol 2007; 102:2850.</a></li><li><a class="nounderline abstract_t">Liu F, Wang GY, Li ZS. Cap-assisted hemoclip application with forward-viewing endoscope for hemorrhage induced by endoscopic sphincterotomy: a prospective case series study. BMC Gastroenterol 2015; 15:135.</a></li><li><a class="nounderline abstract_t">Chon HK, Kim TH. Endoclip therapy of post-sphincterotomy bleeding using a transparent cap-fitted forward-viewing gastroscope. Surg Endosc 2017; 31:2783.</a></li><li><a class="nounderline abstract_t">Aranez JL, Miller J, Hughes M, et al. A novel, duodenoscope-friendly endoscopic clip for treating massive upper-GI bleeding secondary to a Dieulafoy lesion. VideoGIE 2018; 3:205.</a></li><li><a class="nounderline abstract_t">Itoi T, Yasuda I, Doi S, et al. Endoscopic hemostasis using covered metallic stent placement for uncontrolled post-endoscopic sphincterotomy bleeding. Endoscopy 2011; 43:369.</a></li><li><a class="nounderline abstract_t">Valats JC, Funakoshi N, Bauret P, et al. Covered self-expandable biliary stents for the treatment of bleeding after ERCP. Gastrointest Endosc 2013; 78:183.</a></li><li><a class="nounderline abstract_t">Hormati A, Zamani F, Mohaddes M, et al. An Unusual Treatment for Massive and Refractory Bleeding after Endoscopic Retrograde Cholangiopancreatography. Middle East J Dig Dis 2019; 11:116.</a></li><li><a class="nounderline abstract_t">Odemis B, Shorbagi A, Yurdakul M, et al. Percutaneous placement of a biliary self-expandable metallic stent for severe post-ERCP bleeding. Gastrointest Endosc 2014; 80:187.</a></li><li><a class="nounderline abstract_t">Canena J, Liberato M, Horta D, et al. Short-term stenting using fully covered self-expandable metal stents for treatment of refractory biliary leaks, postsphincterotomy bleeding, and perforations. Surg Endosc 2013; 27:313.</a></li><li><a class="nounderline abstract_t">Ogura T, Masuda D, Takeuchi T, et al. Novel covered pancreatic metal stents for the treatment of bleeding after endoscopic pancreatic sphincterotomy. Gastrointest Endosc 2016; 83:1293.</a></li><li><a class="nounderline abstract_t">Appleby VJ, Hutchinson JM, Beckett CJ, Moreea S. Use of the haemostatic agent TC-325 in the treatment of bleeding secondary to endoscopic retrograde cholangiopancreatography sphincterotomy. QJM 2015; 108:79.</a></li><li><a class="nounderline abstract_t">Orlandini B, Schepis T, Tringali A, et al. Fibrin glue injection: Rescue treatment for refractory post-sphincterotomy and post-papillectomy bleedings. Dig Endosc 2021; 33:815.</a></li><li><a class="nounderline abstract_t">Mosca S, Galasso G. Immediate and late bleeding after endoscopic sphincterotomy. Endoscopy 1999; 31:278.</a></li><li><a class="nounderline abstract_t">So YH, Choi YH, Chung JW, et al. Selective embolization for post-endoscopic sphincterotomy bleeding: technical aspects and clinical efficacy. Korean J Radiol 2012; 13:73.</a></li><li><a class="nounderline abstract_t">Dunne R, McCarthy E, Joyce E, et al. Post-endoscopic biliary sphincterotomy bleeding: an interventional radiology approach. Acta Radiol 2013; 54:1159.</a></li><li><a class="nounderline abstract_t">Maleux G, Bielen J, Laenen A, et al. Embolization of post-biliary sphincterotomy bleeding refractory to medical and endoscopic therapy: technical results, clinical efficacy and predictors of outcome. Eur Radiol 2014; 24:2779.</a></li></ol></div><div id="topicVersionRevision">Topic 636 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27546389" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adverse events associated with ERCP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17703388" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19098846" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors for ERCP-related complications: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509029" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence rates of post-ERCP complications: a systematic survey of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816433" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcome and early complications of ERCP: a prospective single center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17322994" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison between endoscopic papillary balloon dilatation and endoscopic sphincterotomy for the treatment of common bile duct stones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29756014" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hemodialysis is a strong risk factor for post-endoscopic sphincterotomy bleeding in patients with choledocholithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863440" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20189503" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A lexicon for endoscopic adverse events: report of an ASGE workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782497" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Complications of endoscopic biliary sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494680" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endoscopic hemostasis in sphincterotomy-induced hemorrhage: its efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15046211" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Patterns of bleeding after endoscopic sphincterotomy, the subsequent risk of bleeding, and the role of epinephrine injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913829" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Decompensated cirrhosis may be a risk factor for adverse events in endoscopic retrograde cholangiopancreatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23869844" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Feasibility of endoscopic retrograde cholangiopancreatography-related procedures in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31060119" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of Hospital Volume and the Experience of Endoscopist on Adverse Events Related to Endoscopic Retrograde Cholangiopancreatography: A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11232684" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31983673" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors for delayed hemorrhage after endoscopic sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643701" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pure versus mixed electrosurgical current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674926" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endoscopic sphincterotomy-induced hemorrhage: a study of risk factors and the role of epinephrine injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28558658" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Therapeutic outcomes of endoscopic papillectomy for ampullary neoplasms: retrospective analysis of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27003996" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Predictors of re-bleeding after endoscopic hemostasis for delayed post-endoscopic sphincterotomy bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34359080" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24836749" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Routine laboratory testing before endoscopic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30487946" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Endoscopic retrograde cholangiopancreatography in cirrhosis - a systematic review and meta-analysis focused on adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36731579" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk of post-sphincterotomy bleeding with antiplatelet and anticoagulant use: a propensity-matched analysis of the U.S. Collaborative Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305758" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673356" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of sustained use of platelet aggregation inhibitors on post-endoscopic sphincterotomy bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26126160" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34796411" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35046182" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Endoscopic retrograde cholangiopancreaticography-related complications - Experience from tertiary care teaching centre over half a decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26621548" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The management of antithrombotic agents for patients undergoing GI endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213054" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endoscopic papillectomy for neoplastic ampullary lesions: A systematic review with pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869722" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Electrophysical factors influencing endoscopic sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31348269" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endoscopic papillary balloon dilation decreases the risk of bleeding in cirrhotic patients compared with endoscopic biliary sphincterotomy: A national population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28337485" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety and efficacy of minimal biliary sphincterotomy with papillary balloon dilation (m-EBS+EPBD) in patients using clopidogrel or anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17912183" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinically significant delayed postsphincterotomy bleeding: a twelve year single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228255" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228256" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Features that may predict hospital admission following outpatient therapeutic ERCP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28545082" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical endoscopic management and outcome of post-endoscopic sphincterotomy bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824118" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treating delayed endoscopic sphincterotomy-induced bleeding: epinephrine injection with or without thermotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23164581" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Factors affecting the success of endoscopic treatment of sphincterotomy bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393333" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Endoscopic hemostasis using monopolar coagulation for postendoscopic sphincterotomy bleeding refractory to injection treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042116" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Post-sphincterotomy bleeding: who, what, when, and how.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472313" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cap-assisted hemoclip application with forward-viewing endoscope for hemorrhage induced by endoscopic sphincterotomy: a prospective case series study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27761747" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Endoclip therapy of post-sphincterotomy bleeding using a transparent cap-fitted forward-viewing gastroscope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30128389" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A novel, duodenoscope-friendly endoscopic clip for treating massive upper-GI bleeding secondary to a Dieulafoy lesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21360425" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Endoscopic hemostasis using covered metallic stent placement for uncontrolled post-endoscopic sphincterotomy bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587846" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Covered self-expandable biliary stents for the treatment of bleeding after ERCP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31380009" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An Unusual Treatment for Massive and Refractory Bleeding after Endoscopic Retrograde Cholangiopancreatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24950647" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Percutaneous placement of a biliary self-expandable metallic stent for severe post-ERCP bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806507" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Short-term stenting using fully covered self-expandable metal stents for treatment of refractory biliary leaks, postsphincterotomy bleeding, and perforations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26555300" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Novel covered pancreatic metal stents for the treatment of bleeding after endoscopic pancreatic sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989779" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Use of the haemostatic agent TC-325 in the treatment of bleeding secondary to endoscopic retrograde cholangiopancreatography sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010074" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fibrin glue injection: Rescue treatment for refractory post-sphincterotomy and post-papillectomy bleedings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344438" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Immediate and late bleeding after endoscopic sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247639" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Selective embolization for post-endoscopic sphincterotomy bleeding: technical aspects and clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892235" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Post-endoscopic biliary sphincterotomy bleeding: an interventional radiology approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063394" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Embolization of post-biliary sphincterotomy bleeding refractory to medical and endoscopic therapy: technical results, clinical efficacy and predictors of outcome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
